What are the recommended antivirals for the treatment of COVID-19?

COVID-19 Antiviral Therapy

First-Line Treatment: Nirmatrelvir/Ritonavir (Paxlovid)

Nirmatrelvir/ritonavir (Paxlovid) is the preferred first-line antiviral for non-hospitalized COVID-19 patients at high risk of hospitalization, initiated within 5 days of symptom onset. 1, 2

Dosing and Administration

• Standard dose: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet), all three tablets taken together twice daily for 5 days 3
• Timing: Must be initiated within 5 days of symptom onset 3
• Administration: Can be taken with or without food, at approximately the same time each day 3

Dose Adjustments for Renal Impairment

• Moderate renal impairment (eGFR 30-59 mL/min): 150 mg nirmatrelvir with 100 mg ritonavir twice daily for 5 days 3
• Severe renal impairment (eGFR <30 mL/min) including hemodialysis: 300 mg nirmatrelvir with 100 mg ritonavir once on Day 1, then 150 mg nirmatrelvir with 100 mg ritonavir once daily on Days 2-5 (administer after hemodialysis on dialysis days) 3
• Severe hepatic impairment (Child-Pugh Class C): Not recommended 3

Efficacy Data

• Mortality reduction: 73% reduction in 28-day mortality (RR 0.269,95% CI 0.179-0.370) 4
• Hospitalization reduction: 26% reduction in 28-day hospitalization risk (RR 0.742,95% CI 0.689-0.812) 4
• In the pivotal trial, nirmatrelvir/ritonavir reduced hospital admission or death to 0.77% versus 7.01% in placebo 1

Critical Drug Interaction Warning

Before prescribing nirmatrelvir/ritonavir, you MUST review all patient medications for potentially life-threatening drug interactions. 3, 5

• Ritonavir is a potent CYP3A4 inhibitor that can cause severe, life-threatening, or fatal drug interactions 3
• Contraindicated medications include those highly dependent on CYP3A4 for clearance (e.g., certain statins, antiarrhythmics, sedatives, ergot derivatives) 3
• Requires dose adjustment or monitoring: Immunosuppressants (tacrolimus, cyclosporine), calcium channel blockers, and many others 3, 5
• The 5-day treatment course limits but does not eliminate interaction risks 5

Common Side Effects

• Dysgeusia (altered taste): 5% of patients 3
• Diarrhea: 3% of patients 3
• Treatment-related adverse events are approximately twice as common as placebo (RR 2.06,95% CI 1.44-2.95) but are generally mild 6

---

Second-Line Treatment: Remdesivir

Remdesivir is the preferred alternative when nirmatrelvir/ritonavir is contraindicated due to drug interactions or unavailable. 1, 2, 7

When to Choose Remdesivir Over Nirmatrelvir/Ritonavir

• Problematic drug interactions: Patients on medications that cannot be safely adjusted or interrupted 1, 7
• Pregnancy: Remdesivir is preferred due to molnupiravir's mutagenic concerns 1
• Children: Remdesivir avoids molnupiravir's effects on bone growth 1

Efficacy

• Remdesivir probably results in important reduction in hospital admission (moderate certainty) 1
• In one network meta-analysis, remdesivir showed the highest probability of preventing hospitalization (P-score 0.99) compared to nirmatrelvir/ritonavir (0.64) and molnupiravir (0.26), though this was based on indirect comparisons 8
• Particularly effective in patients with low-flow oxygen requirements and symptom duration less than 10 days 1

Practical Considerations

• Route: Intravenous administration required, which is a practical disadvantage compared to oral nirmatrelvir/ritonavir 1
• Duration: Short course reduces risk of progression to severe COVID-19/hospitalization (0.7% vs 5.3%) 1

---

Third-Line Treatment: Molnupiravir

Molnupiravir should only be used when both nirmatrelvir/ritonavir and remdesivir are contraindicated or unavailable, and only in high-risk patients. 1, 2

Why Molnupiravir is Third-Line

• Inferior efficacy: Smaller reduction in hospitalization compared to nirmatrelvir/ritonavir (moderate certainty) 1
• Safety concerns: Potential for carcinogenesis based on preclinical mutagenic data (very low certainty) 1
• Contraindications: Should not be used in children (bone growth concerns), pregnant individuals (mutagenic concerns), or those of childbearing potential 1

Efficacy

• Reduces hospitalization or death (6.8% vs 9.7% in placebo) 1, 7
• Probably reduces mortality (moderate certainty) 1

Conditional Recommendation Against Use

• Moderate-risk patients: Conditional recommendation AGAINST use 1
• Low-risk patients: Conditional recommendation AGAINST use 1
• High-risk patients only: Conditional recommendation FOR use when superior options unavailable 1

---

Risk Stratification for Treatment Decisions

High-Risk Patients (Treatment Strongly Indicated)

• Age ≥65 years 2
• Immunocompromised status including hematological malignancies, solid organ transplant, HIV with low CD4 count 1, 2
• Multiple comorbidities: Diabetes, chronic kidney disease, cardiovascular disease, chronic lung disease, obesity 2
• Unvaccinated or vaccine non-responders 2

Moderate-Risk Patients

• Some risk factors but lower baseline hospitalization risk 1
• Treatment decisions should weigh drug interactions and individual risk factors 1
• Nirmatrelvir/ritonavir is conditionally recommended; many patients would value the hospitalization reduction 1

Low-Risk Patients

• Conditional recommendation AGAINST nirmatrelvir/ritonavir due to trivial benefit (high certainty for mortality and hospitalization) 1

---

Special Populations

Immunocompromised Patients with Hematological Malignancies

• Antivirals are particularly important due to prolonged viral phase and higher risk of severe disease 1
• Consider high-titer convalescent plasma for seronegative patients who fail to respond to antivirals 1, 2
• Inhaled interferon beta-1a may be considered as adjunctive therapy 1, 2
• Remdesivir independently associated with lower mortality in observational studies of hematologic malignancy patients 1

Hospitalized Patients Requiring Supplemental Oxygen

• Systemic corticosteroids (dexamethasone) are the cornerstone of therapy 2
• Consider adding tocilizumab or baricitinib to corticosteroids to reduce disease progression and mortality 2
• Antivirals have limited role once patients progress to severe disease requiring oxygen 1

---

Critical Pitfalls to Avoid

Drug Interaction Oversights

The most dangerous pitfall is failing to check for drug interactions before prescribing nirmatrelvir/ritonavir. 2, 3, 5

• Review ALL medications, including over-the-counter and herbal supplements 3
• Common problematic interactions: statins (especially simvastatin, lovastatin), immunosuppressants, antiarrhythmics, anticoagulants, benzodiazepines 3, 5
• When interactions exist, consider remdesivir as alternative rather than denying antiviral therapy entirely 1, 5

Timing Errors

• Must initiate within 5 days of symptom onset for all oral antivirals 3
• Delayed treatment significantly reduces efficacy 1

Inappropriate Denial of Treatment

• The potential for viral rebound should NOT deter prescribing antivirals 9
• Rebound occurs with similar frequency in treated and untreated patients (no statistically significant difference in four studies including one RCT) 9
• No hospitalizations or deaths reported among patients experiencing rebound 9

Combination Therapy

• Do NOT combine antiviral therapies - no evidence supports this approach 1

HIV Resistance Risk

• In patients with uncontrolled or undiagnosed HIV-1 infection, ritonavir exposure may lead to HIV protease inhibitor resistance 3
• Consider HIV testing in appropriate clinical contexts before prescribing 3

---

Contraindications to Nirmatrelvir/Ritonavir

• History of clinically significant hypersensitivity to nirmatrelvir or ritonavir 3
• Co-administration with drugs highly dependent on CYP3A4 where elevated concentrations cause serious/life-threatening reactions 3
• Co-administration with potent CYP3A inducers that would reduce nirmatrelvir/ritonavir levels and risk treatment failure 3

---

Equity Considerations

• Most trial data comes from younger patients (<65 years: 87.1%), white ethnicity (71.5%), and upper-middle or high-income countries (92.1% of study centers) 6
• Treatment effects favored nirmatrelvir/ritonavir in white ethnic groups, while effects in other ethnic groups were less certain 6
• When availability is limited, prioritize high-risk patients for treatment 1